Hans-Peter Brunner-La Rocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481812/publications.pdf Version: 2024-02-01

		136740	123241
120	4,307	32	61
papers	citations	h-index	g-index
121	101	101	5824
121	121		J024
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	2.9	605
2	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	2.9	252
3	Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 1006-1014.	2.9	198
4	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
5	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. European Heart Journal, 2018, 39, 864-873.	1.0	132
6	sST2 Predicts Outcome in ChronicÂHeartÂFailure Beyond NTâ^'proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	1.2	126
7	Contemporary Drug Treatment ofÂChronic Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2019, 7, 13-21.	1.9	122
8	Relevance of cardiac parvovirus <scp>B19</scp> in myocarditis and dilated cardiomyopathy: review of the literature. European Journal of Heart Failure, 2016, 18, 1430-1441.	2.9	108
9	Heart failure with midâ€range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (<scp>TIMEâ€CHF</scp>). European Journal of Heart Failure, 2017, 19, 1586-1596.	2.9	108
10	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	1.9	104
11	Validation of the HFAâ€PEFF score for the diagnosis of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 413-421.	2.9	101
12	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA Journal, 2019, 10, 445-464.	3.3	96
13	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680.	1.0	96
14	End-of-life preferences of elderly patients with chronic heart failure. European Heart Journal, 2012, 33, 752-759.	1.0	95
15	Which heart failure patients profit from natriuretic peptide guided therapy? A metaâ€analysis from individual patient data of randomized trials. European Journal of Heart Failure, 2015, 17, 1252-1261.	2.9	95
16	Long-Term Effect of a School-Based Physical Activity Program (KISS) on Fitness and Adiposity in Children: A Cluster-Randomized Controlled Trial. PLoS ONE, 2014, 9, e87929.	1.1	79
17	Prognostic Relevance of Gene-Environment Interactions in Patients WithÂDilated Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 1313-1323.	1.2	76
18	Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). European Heart Journal, 2007, 28, 719-725.	1.0	74

#	Article	IF	CITATIONS
19	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004228.	1.6	65
20	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 973-982.	2.9	65
21	Initial Imaging-Guided Strategy VersusÂRoutine Care in Patients WithÂNon–ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2466-2477.	1.2	58
22	Comprehensive inâ€hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	2.9	57
23	Inflammation in HFpEF: Key or circumstantial?. International Journal of Cardiology, 2015, 189, 259-263.	0.8	51
24	Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005220.	1.6	51
25	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	2.9	50
26	Cost-Effectiveness of N-Terminal Pro-B-Type Natriuretic-Guided Therapy in Elderly Heart Failure Patients. JACC: Heart Failure, 2013, 1, 64-71.	1.9	44
27	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. Cerebrovascular Diseases Extra, 2018, 7, 140-152.	0.5	44
28	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	2.9	43
29	Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay. Journal of Translational Medicine, 2015, 13, 129.	1.8	40
30	Value of Speckle Tracking–Based Deformation Analysis in Screening Relatives ofÂPatients With Asymptomatic Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2020, 13, 549-558.	2.3	40
31	Reasons for readmission after hospital discharge in patients with chronic diseases—Information from an international dataset. PLoS ONE, 2020, 15, e0233457.	1.1	39
32	Impact of worsening renal function related to medication in heart failure. European Journal of Heart Failure, 2015, 17, 159-168.	2.9	37
33	Challenges in personalised management of chronic diseases—heart failure as prominent example to advance the care process. EPMA Journal, 2015, 7, 2.	3.3	35
34	The combination of carboxyâ€ŧerminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy–ÂA multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. European Journal of Heart Failure, 2021, 23, 933-944.	2.9	34
35	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	0.8	32
36	Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. European Journal of Preventive Cardiology, 2019, 26, 1399-1407.	0.8	31

#	Article	IF	CITATIONS
37	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. Stroke, 2019, 50, 3369-3375.	1.0	29
38	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	0.8	28
39	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€terminal proâ€Bâ€type natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	2.9	26
40	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	0.9	26
41	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus <scp>B19</scp> persistence: a prospective, doubleâ€blind, randomized, placeboâ€controlled clinical trial. European Journal of Heart Failure, 2021, 23, 302-309.	2.9	24
42	Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	0.7	24
43	Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics. BMC Geriatrics, 2015, 15, 167.	1.1	23
44	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	2.9	23
45	Acute chest pain in the high-sensitivity cardiac troponin era: A changing role for noninvasive imaging?. American Heart Journal, 2016, 177, 102-111.	1.2	20
46	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	1.5	20
47	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	1.9	20
48	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case–control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	1.5	19
49	Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. International Journal of Cardiology, 2020, 300, 245-251.	0.8	19
50	Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study. Cardiovascular Diabetology, 2020, 19, 88.	2.7	18
51	Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME HF trial. European Journal of Heart Failure, 2020, 22, 701-709.	2.9	18
52	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. JACC: Cardiovascular Imaging, 2021, 14, 176-185.	2.3	18
53	A global longitudinal strain cutâ€off value to predict adverse outcomes in individuals with a normal ejection fraction. ESC Heart Failure, 2021, 8, 4343-4345.	1.4	17
54	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2021, 23, 74-84.	0.5	17

#	Article	IF	CITATIONS
55	Heart failure with preserved, midâ€range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Failure, 2022, 9, 363-372.	1.4	17
56	Clinical Interpretation of Elevated Concentrations of Cardiac Troponin T, but Not Troponin I, in Nursing Home Residents. Journal of the American Medical Directors Association, 2015, 16, 884-891.	1.2	16
57	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	2.9	16
58	Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. American Journal of Medicine, 2019, 132, e679-e692.	0.6	15
59	Loop diuretics in chronic heart failure: how to manage congestion?. Heart Failure Reviews, 2019, 24, 17-30.	1.7	15
60	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	1.4	15
61	Risk Stratification With the Use of Serial N-Terminal Pro–B-Type Natriuretic Peptide Measurements During Admission and Early After Discharge in Heart Failure Patients: Post Hoc Analysis of the PRIMA Study. Journal of Cardiac Failure, 2014, 20, 881-890.	0.7	14
62	Putting AI at the centre of heart failure care. ESC Heart Failure, 2020, 7, 3257-3258.	1.4	14
63	N-Terminal Pro–B-Type Natriuretic Peptide–Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF. Journal of Cardiac Failure, 2017, 23, 382-389.	0.7	13
64	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. European Journal of Preventive Cardiology, 2021, 28, 957-965.	0.8	13
65	Diabetes and treatment of chronic heart failure in a large realâ€world heart failure population. ESC Heart Failure, 2022, 9, 353-362.	1.4	13
66	Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study. Diabetes and Vascular Disease Research, 2016, 13, 278-285.	0.9	12
67	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	1.8	12
68	Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF. Clinical Research in Cardiology, 2020, 109, 1155-1164.	1.5	12
69	Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. European Journal of Internal Medicine, 2018, 57, 61-69.	1.0	11
70	Cerebral cortical microinfarcts: A novel MRI marker of vascular brain injury in patients with heart failure. International Journal of Cardiology, 2020, 310, 96-102.	0.8	11
71	Determinants of acceptance of patients with heart failure and their informal caregivers regarding an interactive decision-making system: a qualitative study. BMJ Open, 2021, 11, e046160.	0.8	11
72	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	1.4	11

#	Article	IF	CITATIONS
73	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 761-769.	1.8	11
74	Acute heart failure and iron deficiency: a prospective, multicentre, observational study. ESC Heart Failure, 2022, 9, 398-407.	1.4	11
75	What to consider when implementing a tool for timely recognition of palliative care needs in heart failure: a context-based qualitative study. BMC Palliative Care, 2022, 21, 1.	0.8	11
76	Interaction Between Pulmonary Hypertension and Diastolic Dysfunction in an Elderly Heart Failure Population. Journal of Cardiac Failure, 2014, 20, 98-104.	0.7	10
77	Iron i.v. in heart failure: ready for implementation?. European Heart Journal, 2015, 36, 645-647.	1.0	10
78	Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. Cost Effectiveness and Resource Allocation, 2018, 16, 55.	0.6	10
79	Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine. EPMA Journal, 2018, 9, 161-173.	3.3	10
80	Characteristics for a tool for timely identification of palliative needs in heart failure: The views of Dutch patients, their families and healthcare professionals. European Journal of Cardiovascular Nursing, 2020, 19, 711-720.	0.4	10
81	Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. International Journal of Cardiology, 2015, 191, 286-293.	0.8	9
82	Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry. International Journal of Cardiology, 2020, 308, 60-66.	0.8	9
83	Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. ESC Heart Failure, 2022, 9, 1463-1470.	1.4	9
84	Serum Matrix Metalloproteinases and Left Atrial Remodeling—The Hoorn Study. International Journal of Molecular Sciences, 2020, 21, 4944.	1.8	8
85	Differential Prognostic Impact of Resting Heart Rate in Older Compared With Younger Patients With Chronic Heart Failure—Insights From TIME-CHF. Journal of Cardiac Failure, 2015, 21, 347-354.	0.7	7
86	Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008727.	2.1	6
87	A Home Hospitalisation Strategy for Patients with an Acute Episode of Heart Failure Using a Digital Health-Supported Platform: A Multicentre Feasibility Study – A Rationale and Study Design. Cardiology, 2021, 146, 793-800.	0.6	6
88	Treatment of heart failure in nursing home residents. Journal of Geriatric Cardiology, 2016, 13, 44-50.	0.2	6
89	Heart failure and COPD: Time to SHIFT?. International Journal of Cardiology, 2014, 172, 293-294.	0.8	5
90	Biomarker Guided Therapy in Chronic Heart Failure. Cardiac Failure Review, 2015, 1, 96.	1.2	5

6

#	Article	IF	CITATIONS
91	Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. Clinical Research in Cardiology, 2021, 110, 1221-1233.	1.5	5
92	Future perspective of heart failure care: benefits and bottlenecks of artificial intelligence and eHealth. Future Cardiology, 2021, 17, 917-921.	0.5	5
93	Pulmonary and right ventricular dysfunction are frequently present in heart failure irrespective of left ventricular ejection fraction. Heart Asia, 2017, 9, e010914.	1.1	4
94	Professionals guidance about palliative medicine in chronic heart failure: a mixed-method study. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002580.	0.8	4
95	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	4
96	Prognostic Value of the Change in Heart Rate From the Supine to the Upright Position in Patients With Chronic Heart Failure. Journal of the American Heart Association, 2016, 5, .	1.6	3
97	Unravelling heart failure nurses' education: Content comparison of heart failure nurses' education in three European Society of Cardiology states and the Heart Failure Association heart failure curriculum. European Journal of Cardiovascular Nursing, 2019, 18, 711-719.	0.4	3
98	Soluble CD146—an underreported novel biomarker of congestion: a comment on a review concerning congestion assessment and evaluation in acute heart failure. Heart Failure Reviews, 2021, 26, 731-732.	1.7	3
99	Helping to understand heart failure with preserved ejection fraction. European Heart Journal, 2018, 39, 2836-2838.	1.0	2
100	Do chronic heart failure patients receive optimal decongestive interventions in a realâ€life setting? Letter regarding the article †Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry'. European Journal of Heart Failure, 2021, 23, 342-342.	2.9	2
101	Prognostic value of signs and symptoms in heart failure patients using remote telemonitoring. Journal of Telemedicine and Telecare, 2024, 30, 180-185.	1.4	2
102	Worsening Renal Function in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 70-72.	1.2	1
103	Just air good enough in pulmonary hypertension?. European Heart Journal, 2017, 38, 1169-1171.	1.0	1
104	Guiding Heart Failure Therapy AfterÂGUIDE-IT. Journal of the American College of Cardiology, 2018, 72, 2563-2566.	1.2	1
105	Risk stratification and role for additional diagnostic testing in patients with acute chest pain and normal high-sensitivity cardiac troponin levels. PLoS ONE, 2018, 13, e0203506.	1.1	1
106	Nonfocal transient neurological attacks are related to cognitive impairment in patients with heart failure. Journal of Neurology, 2019, 266, 2035-2042.	1.8	1
107	The Reply. American Journal of Medicine, 2020, 133, e330-e332.	0.6	1
108	What do we need to better understand the role of biomarkers in heart failure?. International Journal of Cardiology, 2020, 304, 93-94.	0.8	1

#	Article	IF	CITATIONS
109	Clinical Long-Term Response to Cardiac Resynchronization Therapy Is Independent of Persisting Echocardiographic Markers of Dyssynchrony. Cardiology Research, 2014, 5, 163-170.	0.5	1
110	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	0.6	1
111	41â€∫Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure. European Heart Journal Supplements, 2021, 23, .	0.0	1
112	Better outcome at lower costs after implementing a CRTâ€care pathway: comprehensive evaluation of realâ€world data. ESC Heart Failure, 0, , .	1.4	1
113	Evaluation of Left Ventricular Endocardial Cardiac Resynchronization Therapy in a Non-responder with Ventricular Arrhythmias. Indian Pacing and Electrophysiology Journal, 2014, 14, 32-36.	0.3	0
114	An old debate still in the βâ€phase?. European Journal of Heart Failure, 2018, 20, 557-559.	2.9	0
115	The importance of electrocardiographic followâ€up in heart failure. European Journal of Heart Failure, 2020, 22, 2380-2382.	2.9	0
116	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. Alzheimer's and Dementia, 2020, 16, e042892.	0.4	0
117	Title is missing!. , 2020, 15, e0233457.		0
118	Title is missing!. , 2020, 15, e0233457.		0
119	Title is missing!. , 2020, 15, e0233457.		0
120	Title is missing!. , 2020, 15, e0233457.		0